Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events-Reference-Cited by-同舟云学术

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events

Published:2018-05-27 Issue:10 Volume:97 Page:1803-1808
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Molica Matteo^ORCID,Scalzulli Emilia,Colafigli Gioia,Fegatelli Danilo Alunni,Massaro Fulvio,Latagliata Roberto,Foà Robin,Breccia Massimo

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3375-9/fulltext.html

Reference16 articles.

1. Jabbour E, Deininger M, Hochhaus A (2011) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25(2):201–210

2. Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F, Botey A (2003) Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 44(7):1239–1241

3. Barta VS, Uppal NN, Pullman JM, Levy AT, Jhaveri KD (2017) Acute tubular injury associated with imatinib (Gleevec): a case report and review of the literature. J Onco-Nephrol 1(1):57–61

4. Marcolino MS, Boersma E, Clementino NC et al (2011) Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 22(9):2073–2079

5. Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE (2015) Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894–3904

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa;eJHaem;2024-07-31

2. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-12

3. The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia;Hemato;2023-07-14

4. Real-world Management of CML: Outcomes and Treatment Patterns;Current Hematologic Malignancy Reports;2023-07-03

5. A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia;Frontiers in Medicine;2023-05-05